Drovix.
Three nested concentric rings — capital, risk, and balance-sheet layers
Education

The Balance-Sheet Cost of Leverage: What Funding Stress Tells You About Your Counterparty

Leverage is not free, and the funding-stress component of its cost is paid by your counterparty even when nothing visibly bad has happened to you. A counterparty that does not understand its own funding curve is a counterparty whose spread will move on you for reasons you cannot diagnose.

HomeResourcesInsights & News
18 May 2026Drovix Research Desk7 min

There is a quiet line in every institutional FX broker's P&L that no marketing deck mentions: the funding cost of the inventory they are carrying for you. It is paid in basis points per day, it varies with the broker's own balance-sheet position, and on the days the broker's funding curve moves, your spread moves — for reasons that have nothing to do with your trade and everything to do with the broker's overnight repo desk.

Understanding the structure of that cost is the difference between a counterparty relationship that is durable through a stress cycle and one that quietly degrades the first time conditions tighten.

Three nested concentric rings — capital, risk, and balance-sheet layers
Three nested concentric rings — capital, risk, and balance-sheet layers

Where the cost comes from

When you take liquidity from a broker, the broker either internalises the position into its existing inventory or externalises it via a hedge to a wholesale counterparty. The internalised portion sits on the broker's balance sheet and costs the broker funding — overnight, term, and through any unscheduled events that require additional margin against that position.

The funding cost is real and is paid in two ways: an explicit interest cost (the broker is borrowing to fund the position, either via repo against collateral or via unsecured funding lines) and an implicit capital cost (the position consumes regulatory capital, which has an opportunity cost relative to its alternative deployment).

On a calm Tuesday with abundant funding liquidity and stable rates, the cost is a small known number. On a Wednesday after a hawkish central-bank surprise, the cost rises across the entire industry simultaneously, and brokers' streaming spreads widen in lockstep. Most desks experience this as 'spreads widened today' without ever connecting it to the underlying funding-curve shift.

The three components of funding cost

Overnight

The base case. The broker funds the position overnight in repo against the position itself or in unsecured funding from its treasury. The cost is the overnight rate plus the broker's spread to that rate. For a tier-1 institutional broker the unsecured spread is typically 5-20 bps; for a leveraged-broker model financed via term repo it can be 50-150 bps. Both numbers are floors, not ceilings.

Term

Positions held beyond overnight need term funding, which the broker procures in 1-week to 3-month repo or via the unsecured CP/CD market. The term curve is upward-sloping in normal conditions and inverts in funding stress; an inverted curve is one of the strongest leading indicators that broker spreads are about to widen materially.

Stress

On days when the funding market itself is dislocated — repo specials, CCP margin calls, dealer-balance-sheet constraints around quarter-end — the funding cost spikes by an order of magnitude beyond its normal level. The broker that has not pre-positioned for this experience tightens its spread in real time; the broker that has pre-positioned widens by less.

Stack of horizontal bars of decreasing length — balance-sheet capacity
Stack of horizontal bars of decreasing length — balance-sheet capacity

How this manifests as spread

Brokers that are funding-sensitive widen their spreads on the entire book during a funding-stress day, even on instruments where the underlying market is calm. This is the mechanical answer to the question 'why did my major-pair spread widen today even though nothing happened in the major-pair market'.

Brokers that are funding-resilient — well-capitalised, multi-source funded, with longer-dated funding to match their position lifetimes — widen by less and on a narrower subset of instruments. The differential is observable. A desk that tracks its own historical spread paid to each broker against a public funding-stress index (the FRA-OIS basis, the IOR-RRP differential, dealer CDS spreads) can quantify each broker's funding sensitivity within a quarter of trading data.

What to ask your counterparty

  • What is the average overnight funding cost embedded in your streaming spread on major pairs? A counterparty that cannot answer this is either uninformed about its own cost or unwilling to disclose it; both are signals.
  • What proportion of your funding is overnight versus term? An overnight-dominated funding stack widens more during funding stress; a term-dominated stack is more stable but charges a higher base.
  • Do you pre-position term funding against expected residual inventory, or do you fund it overnight by default? The answer to this question maps directly to the spread behaviour you will see during quarter-end and year-end.
  • What is your unsecured funding spread to the relevant overnight reference rate? Tier-1 institutional brokers are at 5-20 bps; anything materially wider is information about counterparty risk.

Drovix's funding profile

Drovix funds its institutional book through a mix of overnight secured repo against position collateral and term unsecured lines from a panel of tier-1 banks. The mix is approximately 30/70 overnight/term, deliberately weighted toward term to reduce the funding-stress sensitivity of the streaming book. The unsecured spread is publishable on request; the term tenor distribution is publishable on request.

The architecture that allows us to internalise efficiently — and therefore reduce the funding cost of any given inventory level — is part of what makes the spreads we publish economically sustainable. See The Architecture of a Fair Spread for the pricing side; this post is the cost side.

None of this is unique to Drovix in principle. What is increasingly unique in practice is the willingness to discuss the funding stack explicitly with a counterparty who asks. A broker that treats its funding model as confidential is a broker who has not stress-tested its own assumptions and is going to find out alongside its counterparties whether they hold.

Where to go next

→ Institutional Onboarding and Counterparty Due Diligence — the rest of the questions worth asking a counterparty before you start sending size.

→ Correlation Under Stress — the related question of how funding stress and market stress propagate together, and what that means for a hedge's reliability.

Methodology and data

Balance-sheet cost is computed as the all-in funding rate (PB margin + haircut + repo + capital charge) applied to a constant-notional position, expressed in pips per day for FX and in basis points per day for index-CFD. The sample is nine tier-1 PBs and four non-bank prime brokers across the trailing eighteen months. Costs are normalised to a standard reference book; cross-margin offsets and netting benefits are excluded for comparability.

Limitations and scope

PB pricing schedules are commercially negotiated; the published figures here are central-tendency estimates, not quotes. Cross-margin offsets and netting can reduce balance-sheet cost by 20–40% for diversified books, and this benefit is not reflected in the comparable figures. Non-bank PB costs are stable in normal conditions but rerate faster in stress than tier-1 PB costs do.

Further reading

→ Margin Procyclicality and Tier-1 Stress — The stress side of the same cost function. See /blog/margin-procyclicality-tier1-stress.

→ Capacity Planning for Execution Strategies — How the balance-sheet cost flows into per-strategy capacity. See /blog/capacity-planning-for-execution-strategies.

Drovix Research is the in-house institutional desk of Drovix MU Ltd, regulated by the Financial Services Commission of Mauritius. All notes are informational only and do not constitute investment advice, a solicitation, or a recommendation to transact in any financial instrument.

Analyst Desk

Drovix Research Desk

Institutional Research

Drovix Research Desk publishes institutional-grade analysis covering macro events, cross-asset correlations, and execution insights for professional market participants.

Frequently Asked Questions

Q1.Why isn't this just the margin rate?+
Because margin is only one of four components. The all-in figure includes the PB's haircut, the funding rate on the cash leg, and the regulatory capital charge the broker has to hold against the position. A broker that benchmarks only against the margin rate is systematically under-budgeting.
Q2.Are non-bank PBs cheaper?+
Often, yes — in normal conditions. The trade-off is procyclicality: non-bank PB pricing rerates faster in stress because the PB's own funding base is more concentrated. The right answer depends on the broker's tolerance for stress repricing relative to its tolerance for steady-state cost.
Q3.Can we hedge balance-sheet cost?+
Indirectly. The dominant components — margin and funding — can be partially hedged by carrying the offsetting position with the same PB so the netting benefit applies. The capital charge is a regulatory floor and cannot be hedged.

Related Reads

Education

TCA That Actually Drives Decisions: Beyond Implementation Shortfall

Next Read

Education

From RFP to First Fill: A 6-Week Liquidity Onboarding Playbook

Next Read

Education

The True Cost of Institutional Liquidity: Beyond the Quoted Spread

Next Read

Back to Insights
Drovix.

Institutional-grade liquidity, connectivity, and analytics for professional market participants worldwide.

About

  • Why Drovix
  • About Us
  • Technology
  • For Brokers
  • For Hedge Funds & Quants
  • For Family Offices
  • For Prop Trading Firms
  • For Institutions & Corporates
  • DVX Trading Platform
  • Institutional Liquidity
  • Market Making
  • Contact
  • Insights

Compliance

  • Client Eligibility
  • Risk & Controls
  • Regulation
  • Regulatory Status
  • Restricted Jurisdictions
  • Reverse Solicitation
  • Risk Disclosure

Legal

  • Privacy
  • Terms and Agreements
  • Client Agreement
  • Order Execution Policy
  • AML/KYC Policy
  • Cookie Policy
  • Complaints Handling
  • Site map

Professional & Institutional Clients Only: Drovix provides services only to approved professional clients, eligible counterparties and institutional clients where permitted by applicable law. Drovix does not provide services to retail clients through this website and does not accept public deposits or retail deposits.

FSC Mauritius: Drovix (MU) Ltd is authorised and regulated by the Financial Services Commission of Mauritius as an Investment Dealer (Full Service Dealer excluding Underwriting), licence number GB21026813. Regulatory authorisations apply only to the legal entity to which they are granted and do not extend automatically to any affiliated entity, offshore entity, group company or retail-facing brand. Drovix is not currently authorised by the UK Financial Conduct Authority.

No Public / Retail Deposits: Drovix is not a bank and does not accept public deposits or retail deposits. Where margin, collateral or client money is held in connection with an approved institutional relationship, it is handled in accordance with applicable regulatory requirements and the relevant client agreement. Client funds held with Drovix (MU) Ltd are not protected by any government deposit guarantee or investor compensation scheme; the Financial Services Commission of Mauritius does not operate an investor compensation fund.

The information on this website is intended for approved professional clients, eligible counterparties and institutional clients only. It does not constitute investment advice, a solicitation or a recommendation to enter into any transaction. Drovix is not a public exchange, multilateral trading facility (MTF), organised trading facility (OTF), ECN, retail trading venue or retail broker. Drovix may act as principal in bilateral OTC transactions, or arrange the transmission of orders to third-party liquidity providers, in order to maintain best execution under prevailing market conditions.

Reverse Solicitation Notice: The information and services on this website are not directed at or intended for distribution to residents or nationals of any country or jurisdiction where such distribution or use would be contrary to local law or regulation. Approved institutional counterparties access Drovix (MU) Ltd services on their own initiative. Reverse-solicitation arguments cannot be used to bypass retail rules, sanctions or applicable cross-border regulation.

Drovix services are not intended for residents, nationals or entities located in jurisdictions where Drovix is not authorised or permitted to provide services. Restricted jurisdictions include, but are not limited to: Afghanistan, Australia, Barbados, Belarus, Belgium, Burkina Faso, Cameroon, Canada, Central African Republic, Cuba, Democratic Republic of Congo, France, Haiti, Iran, Japan, Libya, Malaysia, Mali, Mozambique, Myanmar, Nicaragua, North Korea, Poland, Russia, Senegal, Sudan, Syria, Tanzania, Ukraine, the United Kingdom, the United States, Venezuela, Yemen and Zimbabwe, together with all jurisdictions on applicable EU, UN, UK, US OFAC and Mauritius sanctions lists. See Restricted Jurisdictions for the full list and policy.

© 2026 Drovix (MU) Ltd. All rights reserved.

Drovix (MU) Ltd is authorised and regulated by the Financial Services Commission (FSC) of Mauritius as an Investment Dealer (Full Service Dealer) under licence number GB21026813.

Drovix (MU) Ltd is not authorised by the United Kingdom Financial Conduct Authority and is not registered with the U.S. SEC, CFTC or NFA. Nothing on this website constitutes a financial promotion under section 21 of the UK Financial Services and Markets Act 2000.

The company operates under drovix.com and is registered at C/o SALVUS (Mauritius) Ltd, Silver Bank Tower, Ground Floor, 18 Bank Street, Cybercity, Ebene 72201 Mauritius.